Related Experiment Video

Updated: Sep 25, 2026

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

The JAK/STAT pathway is not sufficient to sustain the antiproliferative response in an interferon-resistant human

David P Jackson1, Diane Watling, Neil C Rogers

  • 1Cancer Research UK Clinical Centre, St James's University Hospital, Leeds, UK. d.p.jackson@cancermed.leeds.ac.uk

Melanoma Research
|June 5, 2003
PubMed

Insights

Interferon-alpha resistance in melanoma is complex. This study found that the JAK/STAT pathway is intact in resistant cells, suggesting resistance mechanisms lie downstream or outside this pathway.

Area of Science:

  • Oncology
  • Molecular Biology
  • Immunology

Background:

  • Malignant melanoma resistance to interferon-alpha (IFN-α) lacks clear mechanisms and predictive markers.
  • The Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway is crucial for IFN-α signaling and antiproliferative effects.

Purpose of the Study:

  • To investigate if defects in the JAK/STAT signaling pathway contribute to interferon resistance in melanoma.
  • To analyze the JAK/STAT pathway components and function in both IFN-α-sensitive and resistant melanoma cell lines.

Main Methods:

  • In vitro assessment of melanoma cell line response to interferon-alpha.
  • Western blotting to detect JAK/STAT pathway protein components.
  • Electrophoretic mobility shift assay and ribonuclease protection assay to evaluate pathway functionality and interferon-induced gene expression.

Main Results:

  • Both sensitive (MM418) and resistant (MeWo) melanoma cell lines possessed all JAK/STAT pathway components.
  • Functional transcription factors were produced, and antiviral/HLA upregulation responses were intact in both cell lines.
  • No intrinsic defect in the JAK/STAT pathway was identified in the resistant MeWo cell line.

Conclusions:

  • Melanoma's resistance to interferon-alpha is not solely due to defects in the JAK/STAT pathway.
  • Resistance mechanisms likely involve components downstream or additional to the JAK/STAT pathway.
  • The heterogeneity of resistance mechanisms suggests limited clinical utility for JAK/STAT pathway analysis as a sole predictor of interferon response.

More Related Videos

Time-resolved Förster Resonance Energy Transfer Assays for Measurement of Endogenous Phosphorylated STAT Proteins in Human Cells07:12

Time-resolved Förster Resonance Energy Transfer Assays for Measurement of Endogenous Phosphorylated STAT Proteins in Human Cells

Published on: September 9, 2021

Related Concept Videos

The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...